
Peer reviewed version

Link to published version (if available):
10.1021/acs.orglett.7b03057

Link to publication record in Explore Bristol Research
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via ACS Publications at http://pubs.acs.org/doi/abs/10.1021/acs.orglett.7b03057. Please refer to any applicable terms of use of the publisher.

*University of Bristol - Explore Bristol Research*

*General rights*

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Synthesis of Alfaprostol and PGF$_{2\alpha}$ Through 1,4-Addition of an Alkyne to an Enal Intermediate as the Key Step

Hannah Baars‡, Moritz J. Classen‡, Varinder K. Aggarwal*

School of Chemistry, University of Bristol, Cantock’s Close, Bristol, BS8 1TS, U.K.

Supporting Information Placeholder

ABSTRACT: The veterinary drug Alfaprostol and prostaglandin PGF$_{2\alpha}$ have been synthesized in just 9 steps. The strategy involved the conjugate addition of an alkyne to a bicyclic enal, available in three steps by a proline-catalyzed aldol reaction of succinaldehyde. In the case of Alfaprostol, this resulted in the shortest synthesis reported to date. For PGF$_{2\alpha}$, this approach improved our previous route by making the 1,4-addition and ozonolysis more operationally simple.

Prostaglandins are involved in many reproductive processes in mammals. Control of such processes, particularly in veterinary medicine, is critical to food production and animal welfare. For example, prostaglandin PGF$_{2\alpha}$ (1) is known for its luteolytic effect (degradation of the corpus luteum) in cattle. This activity is exploited in veterinary practice for the timing of insemination and increasing reproductive efficiency. Alfaprostol (2) was developed as a more stable and selective analogue of PGF$_{2\alpha}$ and is widely used as a potent luteolytic agent in cows and mares. In addition to its application in the treatment of glaucoma, continued research on PGF$_{2\alpha}$ and its analogues (including Alfaprostol) have uncovered a diverse array of new biological activity from reduction of adipose tissue, to the treatment of neuropsychiatric conditions (e.g. bipolar disorders). These new applications warrant renewed and improved syntheses of this important class of compounds.

Figure 1. Prostaglandin PGF$_{2\alpha}$ and its synthetic analogue Alfaprostol.

Whilst numerous diverse strategies have been reported for the synthesis of PGF$_{2\alpha}$, strategies towards Alfaprostol have been more limited. In fact, they all utilize the Corey lactone as an intermediate, only differing in the method for the introduction of the alkyne moiety (Scheme 1A). Gandolfi et al. applied a sequence of HWE olefination, bromination and double dehydrobromination to install the triple bond. Monteiro et al. used a Seyferth-Gilbert homologation to give the alkyne directly, which was converted into a stannane and finally coupled with acyl chloride in a Stille coupling. Both approaches required ca. 17 steps from cyclopentadiene.

Scheme 1. Previous and current strategy towards Alfaprostol.

A. Previous work

Gandolfi et al.

HWE $\rightarrow$ bromination + dehydrohalogenation

9 steps $\rightarrow$ Alfaprostol

Seyferth-Gilbert

bromination + stannation + Stille coupling

B. Current work

1) (l)-proline (2 mol%) THF (2 w), 20 h, rt

then [B$_n$NH$_3$][TFA] (2 mol%), THF (1 w), 14 h, rt

2) MeOH (2 equiv) Amberlyst 15 MgSO$_4$, 14 h, rt (see ref 12)

4 steps (previous work) $\rightarrow$ PGF$_{2\alpha}$

We recently reported a 7-step synthesis of PGF$_{2\alpha}$ and similarly short syntheses of Latanoprost and Bimatoprost. We employed the (l)-proline catalyzed aldol reaction of
succinaldehyde as the key step to rapidly assemble the bicyclic enal, which was ideally set up to enable the stereoselective incorporation of the remaining side chains (Scheme 1B). Herein, we report the application of this strategy to an 9-step synthesis of Alfaprostol based on the conjugate addition of an alkyne to our key enal intermediate.

1,4-Additions of alkynes to α,β-unsaturated aldehydes are challenging as alkynes usually form stable complexes with copper\textsuperscript{14} (in fact, they have been used as non-transferable groups in mixed organocuprates) and alternative organometallics either led to undesired 1,2-addition or no reaction. There is just one report of the addition of copper acetylides to an enal, which employed iodonitrile silane as an activator.\textsuperscript{15} We initially tested this methodology on lactone \textsuperscript{3}\textsuperscript{3} with the commercially available alkyne 4 (protected as a silyl ether; Scheme 2A).\textsuperscript{7} Under the reported conditions (at −40 °C), we were pleased to find that the addition product 5 was formed, after acidic work up, in good yield (48% \textsuperscript{1}H NMR yield). The yield could be increased to 83% (by \textsuperscript{1}H NMR) by lowering the temperature to −78 °C. Crucial for high yields was the quality of the TMSI, which had to be stored under the exclusion of light, air and moisture.\textsuperscript{16}

**Scheme 2** Model Studies to investigate (a) the 1,4-addition to enal 3 and (b) a 1,4 addition/ozonolysis sequence.

![Scheme 2 Diagram](image)

Next, we explored whether the conditions were also suitable for the 1,4-addition and subsequent ozonolysis with the required hemiacetal 6. Thus, the crude reaction mixture obtained following 1,4-addition was subjected directly to ozonolysis (Scheme 2B). Our standard protocol used in our previous prostaglandin synthesis\textsuperscript{12} involved reaction with ozone, followed by flushing the reaction mixture with a stream of N\textsubscript{2} and subsequent addition of NaBH\textsubscript{4} to reduce the ozonide and reduce the ketone intermediate. However, under these conditions an allene side product was formed instead of the desired alcohol 7. This problem was overcome by reducing the ozonide with PPh\textsubscript{3} before addition of NaBH\textsubscript{4},\textsuperscript{17} leading to the formation of alcohol 7 in 50% yield over the 2 steps.

Having established that the conjugate addition to our enal substrate was feasible, we moved on to the synthesis of Alfaprostol itself. The lower side chain 11 was prepared in 4 steps starting from 3-cyclohexylpropanoic acid (8; Scheme 3). Transformation of acid 8 into the corresponding Weinreb amide, and subsequent coupling with ethynylmagnesium bromide, gave alkyne 9 in 85% yield over 2 steps. Chiral alcohol 10 was obtained by asymmetric CBS-reduction\textsuperscript{18} in 87% yield and 97:3 er. Alcohol 10 was protected as a silyl ether in 93% yield in the final step.

**Scheme 3** Synthesis of the α side chain.

![Scheme 3 Diagram](image)

To complete the synthesis of Alfaprostol (Scheme 4), copper acetylide 12 was generated from alkyne 11 and added to enal 6, to form intermediate silyl enol ether 13. Subsequent ozonolysis and reduction with NaBH\textsubscript{4} furnished alcohol 14 in 56% yield over the two steps, and with complete stereosecontrol over the two newly created stereogenic centers at C\textsubscript{11} and C\textsubscript{12}. Double deprotection of the silyl and acetal groups under acidic conditions gave the hemiacetal intermediate 15, which was used without purification in the subsequent Wittig reaction. Accordingly, treatment of hemiacetal 15 with the commercially available Wittig salt gave Z-alkene 16 with essentially perfect selectivity. Finally, esterification\textsuperscript{19} of acid 16 with methyl iodide completed an 9-step synthesis of Alfaprostol (2) with complete stereosecontrol.

By synthesizing Alfaprostol, we recognized that the conjugate addition of an alkyne to enals 3/6 could also be beneficial for the synthesis of PGF\textsubscript{2α}, and other prostaglandin analogues, for three reasons. Firstly, our original 1,4-addition to the enal required the formation of an organocuprate bearing the required vinyl substituent and a non-transferable thiophene ligand,\textsuperscript{12} and its preparation was time consuming, laborious, and required the use of t-BuLi. Secondly, we had previously required a more functionalized vinyl iodide rather than using the commercially available alkyne directly. Thirdly, the ozonolysis would become simpler and more reliable due to the absence of a second competing double bond, and so timing of the addition of ozone would become less critical. We therefore revisited the synthesis of PGF\textsubscript{2α} (Scheme 5). From our initial studies, we found that the sequence of 1,4-addition of alkyne 4 to enal 6 followed by ozonolysis and reduction with sodium borohydride gave alcohol 7 in good yield and full stereosecontrol, over 2 steps (Scheme 2). The alkyne was converted into E-allylic alcohol 18 by deprotection of the TBDMS group with
Scheme 4. Synthesis of Alfaprostol

Scheme 5. Synthesis of PGF$_{2\alpha}$

TBAF and subsequent Chan-reduction$^{10}$ with Red-Al. Finally, deprotection of the acetal and Wittig olefination gave PGF$_{2\alpha}$ 1.

In conclusion, we have developed short routes towards Alfaprostol (9 steps longest linear sequence, 12 steps in total) and prostaglandin PGF$_{2\alpha}$ (9 steps longest linear sequence, 10 steps in total). Alfaprostol and PGF$_{2\alpha}$ were synthesized in 23% and 18% overall yields from 6, respectively (both were obtained in ~3% overall yield from succinaldehyde; the optimization for the synthesis of 6 is currently ongoing in our laboratories). In comparison to the previous syntheses of Alfaprostol, our key enal intermediate is not only not accessed in substantially fewer steps compared to the Corey lactone, but it is also perfectly set up to introduce the alkyne side chain in an efficient, single-step fashion. This resulted in the marked step count reduction reported here. Furthermore, the conjugate addition of an alkyne to the enal intermediate simplifies both the 1,4-addition and subsequent ozonolysis significantly. The alkyne functionality can be retained or converted into either an alkene or alkane, thereby providing access to an even broader array of important prostaglandin analogues which are currently used in the clinic.

ASSOCIATED CONTENT

Supporting Information
Experimental procedures, characterization data, and NMR spectra for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author
* Email: v.aggarwal@bristol.ac.uk

Author Contributions

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENT

We thank EPSRC for support of this work (EP/M012530/1). H.B. thanks the Deutsche Forschungsgemeinschaft (DFG) for a postdoctoral fellowship. We thank Dr. Jonathan P. Knowles and James Smith (University of Bristol) for helpful discussion.

REFERENCES


(16) A commercial source (Sigma Aldrich) of TMSI was used without further purification. The TMSI was stored over copper turnings, under an inert atmosphere, and in a freezer.


